Pfizer said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months.
Pfizer, in a statement Wednesday, said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months.Between 60,000 and 120,000 older adults are hospitalized with RSV every year and 6,000 to 10,000 older adults die from the virus.The Food and Drug Administration is expected to decide by spring whether to approve Pfizer's vaccine to prevent respiratory syncytial virus, or RSV, in adults ages 60 and older.
Pfizer, in a statement Wednesday, said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months. The FDA is expected to make a final decision on whether to approve the vaccine by May 2023. RSV is a common respiratory virus that causes cold like symptoms in most people, but it can result in severe illness in infants and older adults. Between 60,000 and 120,000 older adults are hospitalized with RSV every year and 6,000 to 10,000 older adults die from the virus.There is no vaccine for RSV.
Pfizer's vaccine candidate was about 86% effective in preventing severe lower respiratory tract illness, defined as three or more symptoms. The vaccine was about 67% effective at preventing milder lower respiratory tract illness, defined as two or more symptoms. "With no RSV vaccines currently available, older adults remain at-risk for RSV disease and potential severe outcomes, including serious respiratory symptoms, hospitalization, and in some cases, even death," said Annaliesa Anderson, Pfizer's head of vaccine research and development.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA set to decide on Pfizer's RSV vaccine by MayPfizer Inc. undefined said Wednesday that its experimental respiratory syncytial virus vaccine received Priority Review from the Food and Drug...
Read more »
Pfizer asks FDA to clear updated COVID shot for kids under 5Pfizer is asking U.S. regulators to authorize its updated COVID-19 vaccine for children under age 5 — not as a booster but part of their initial shots. Children ages 6 months through 4 years already are supposed to get three extra-small doses of the original Pfizer COVID-19 vaccine — each a tenth of the amount adults receive — as their primary series. If the Food and Drug Administration agrees, a dose of Pfizer's bivalent omicron-targeting vaccine would be substituted for their third shot.
Read more »
Pfizer asks FDA to clear updated COVID-19 vaccine for kids under 5If the Food and Drug Administration agrees, a dose of Pfizer's bivalent omicron-targeting vaccine would be substituted for their third shot.
Read more »
Pfizer applies for FDA authorization for Omicron-retooled vaccine booster in kids under 5Pfizer Inc and its German partner BioNTech SE said on Monday they have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization of their Omicron-adapted COVID-19 vaccine booster for children aged 6 months through 4 years.
Read more »
Pfizer asks FDA to clear updated COVID shot for kids under 5Pfizer and its partner BioNTech said Monday that may help prevent severe illness and hospitalization from COVID-19 in little kids, at a time when children’s hospitals already are packed with youngsters hit by other respiratory illnesses.
Read more »